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Comparative Multiple-Dose Pharmacokinetics of Cefotaxime, Moxalactam,
and Ceftazidime
Ruedi Luthy, Jiirg Blaser, Antonio Bonetti,
Hanspeter Simmen, Richard Wise, and
Walter Siegenthaler
The present study was conducted to compare the
pharmacokinetics of three different doses of cefo-
taxime, moxalactam, and ceftazidime and to
evaluate the influence of probenecid on the phar-
macokinetic behavior of these three third-genera-
tion cephalosporins.
Patients and Methods
Six male volunteers received in a crossover fashion
doses of 0.5, 1.0, and 2.0 g of each drug by infu-
sion over a 5-min interval. Doses of 1.0 g were re-
peated after administration of probenecid. For
each dose, 17 blood samples per volunteer were
drawn for documentation of the distribution and
elimination phase of the cephalosporin. The uri-
nary excretion was determined from five quantita-
tive urine collections made over the 24-hr period
after administration of the test drug. Serum and
urine concentrations were assayed by an agar dif-
fusion method. The assay strain for cefotaxime
was resistant to its desacetyl metabolite. The
average coefficient of variation for interassay
precision was 4.6070 ± 0.9070. Serum samples for
the 0.5- and 2.0-g doses of cefotaxime and moxa-
lactam also were analyzed by a method of high-
pressure liquid chromatography (HPLC) that pro-
vided information on the behavior of the desacetyl
metabolite of cefotaxime and the two naturally oc-
curring epimers of moxalactam [1, 2]. The phar-
macokinetic parameters of a two-compartment
open model were adapted to the experimental data
with a nonlinear fitting program. For all statistical
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evaluations the Wilcoxon matched pairs signed
rank test was used. Probabilities of 2a ~ 0.05 were
considered significant.
Results and Discussion
The mean serum concentrations of cefotaxime,
moxalactam, and ceftazidime at 10 min and 6, 8,
and 12 hr are presented in table 1. Serum concen-
trations of moxalactam exceeded those of cef-
tazidime at all times and were distinctly higher
than those of cefotaxime. At 8 and 12 hr the mean
concentrations of cefotaxime were consistently
<0.5 mg/liter, whereas those of ceftazidime and
moxalactam were rv5-10 times higher. For
facilitation of the comparison between the various
doses and drugs, the area under the serum concen-
tration-vs.-time curve (AVC) was normalized by
dividing by the individual dose. Compared with
the value for cefotaxime, the normalized AVC for
moxalactam was three to four times higher and
that for ceftazidime, two to three times higher.
Probenecid increased the AVC for the 1.0-g dose
of cefotaxime about twofold but did not affect
those for moxalactam and ceftazidime significant-
ly. Linear regression analysis of the dose (x [in g])
vs. normalized AVC (y [in mg x hr/liter]) yielded
a slope for cefotaxime (y = 13.14x + 45.12) that
was significantly different from zero (P < 0.001),
a result that indicated a nonlinear increment in
AVC for increasing doses. In contrast, slopes for
moxalactam (y = - 19.36x + 240.09) and ceftazi-
dime (y = -14.59x + 168.51) did not differ sig-
nificantly from zero.
The pharmacokinetic parameters of cefotaxime,
moxalactam, and ceftazidime are summarized in
table 2. Significant differences between the three
compounds in the total volume of distribution
were observed for the 0.5-g dose but not for the
1.0- and 2.0-g doses. Intraindividual comparisons
of the elimination t'h values, total body clearance
rate, and renal clearance rate demonstrated
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Table 1. Mean serum concentrations of drug after infusions over a 5-min interval of cefotaxime, moxalactam, and
ceftazidime in six male volunteers.
Mean ± SD serum level (mg/liter)
Dose, drug Actual dose (g)* 0.17 hr 6 hr 8 hr 12 hr
0.5 g
Cefotaxime 0.58 37.8 ± 7.1 0.3t <0.1 <0.1
Moxalactam 0.47 63.3 ± 6.0 4.2 ± 1.7 2.2 ± 0.6 0.7 ± 0.2
Ceftazidime 0.48 49.9 ± 8.0 2.1 ± 0.5 1.0 ± 0.3 0.3 ± 0.1
1 g
Cefotaxime 1.06 80.8 ± 14.1 0.4 ± 0.1 <0.1 <0.1
Moxalactam 0.99 120 ± 12.4 8.2 ± 2.0 4.7 ± 1.0 1.4 ± 0.5
Ceftazidime 0.96 107 ± 18.0 4.4 ± 1.4 2.1 ± 0.7 0.5 ± 0.3
2g
Cefotaxime 2.02 174 ± 36.7 0.9 ± 0.5 0.5+ <0.1
Moxalactam 1.87 210 ± 30.8 14.2 ± 2.4 8.0 ± 1.8 2.6 ± 0.8
Ceftazidime 1.94 181 ± 23.2 6.6 ± 1.5 3.8 ± 0.9 1.1 ± 0.5
1 g + probenecid'[
Cefotaxime 0.96 109 ± 12.3 1.4 ± 0.7 0.611 <0.1
Moxalactam 1.10 111± 10.8 10.0 ± 1.7 6.2 ± 1.2 2.7 ± 0.8
Ceftazidime 0.97 98.9 ± 12.5 4.2 ± 0.6 2.1 ± 0.5 0.5 ± 0.2
* Mean value of the doses administered to the six volunteers.
t The SD for three volunteers was 0.1; that for the other three was <0.1.
+ The SD for three volunteers was 0.4; that for the other three was <0.1.
§ Probenecid was administered at a dosage of 0.5 g every 6 hr on the day before testing and 1.0 g at 30 min before administration
of the test drug.
II The SD for five volunteers was 0.4; that for the remaining volunteer was <0.1.
significant differences between these antibiotics.
The t 1;2 values, calculated from the 0.5-, 1.0-, and
2.0-g doses, averaged 2.34, 1.95, and 1.16 hr for
moxalactam, ceftazidime, and cefotaxime, respec-
tively. The 24-hr urinary recovery was highest for
moxalactam (75% ± 4070), followed by ceftazi-
dime (68070 ± 11 %) and cefotaxime (53% ± 6%).
The total body and renal clearance rates of cefo-
taxime decreased significantly with an increase in
the dose. In contrast to the findings for moxalac-
tam and ceftazidime, the ratio of renal clearance
rate to creatinine clearance rate for cefotaxime in-
dicated considerable tubular secretion of the drug.
The influence of probenecid on serum concen-
tration, t 1;2, AUe, volume of distribution, and
clearance rate was most obvious with cefotaxime.
Saturation of tubular secretion led to serum con-
centrations with the 1.0-g dose of cefotaxime that
at 2 hr already were higher than those achieved
with the 2.0-g dose. The renal clearance rate of
this drug decreased by almost 50% and the AUe
doubled when probenecid was administered. This
finding is in contrast to the findings for moxalac-
tam and ceftazidime, where the marginal influence
of this agent is of no practical significance.
The level of the desacetyl metabolite of cefotax-
ime, determined by HPLe, peaked 45 min after
administration. The average levels of the metabo-
lite were 2.7 ± 1.0 and 9.8 ± 1.8 mg/liter for the
0.5- and 2.0-g dose, respectively, and the half lives
for these doses were approximately twice those of
cefotaxime (1.9 ± 0.7 hr and 1.4 ± 0.4 hr, respec-
tively). After the 0.5-g dose the AUe for the
desacetyl metabolite was 31% ± 12% of the AUe
for cefotaxime. For the 2.0-g dose this proportion
decreased to 18% ± 2070, a result suggesting that
desacetylation may not follow first-order kinetics.
Freshly prepared solutions of moxalactam con-
tain two epimers, designated R(-) and S(-), in
approximately equal amounts. The serum protein
binding of the R(-) epimer averages 53%; that of
the S(-) epimer is rv67% [3]. The antimicrobial
activity of the former epimer is approximately
double that of S(-) [1].
Analysis of the two epimers revealed that their
pharmacokinetic behaviors are different. At 10
min after iv administration, the ratio of the R(-)
to the S(-) epimer was 0.84; it decreased rapidly
to 0.5 at 5 hr-i.e., there was twice as much of the
S(-) epimer as of the R(-) epimer. At this time
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the antimicrobial activity, as determined by the
agar diffusion assay, was reduced by one-fourth
when compared with the concentration measured
by HPLC analysis.
No adverse effects were recorded throughout
the study. Chemistry profiles, blood cell counts,
urinalysis results, and creatinine clearance rates
remained within normal limits.
The present study demonstrated that significant
differences exist in the pharmacokinetic behavior
of cefotaxime, moxalactam, and ceftazidime.
From this standpoint, it appears reasonable to
conclude that moxalactam and possibly cef-
Luthy et 01.
tazidime could be administered twice a day and
cefotaxime, three or even four times a day.
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